Clinical trial
Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction
NCT00430885 · Oslo University Hospital, Other · Completed
Key facts
| NCT number | NCT00430885 |
|---|---|
| Title | Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction |
| Official title | Phase III Study of Intravenous Immunglobulin (IVIG) in Patients With Heart Failure After Myocardial Infarction |
| Lead sponsor | Oslo University Hospital, Other |
| Collaborators | Helse Stavanger HF |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myocardial Infarction |
| Intervention type | Drug |
| Interventions | Octagam (IVIG) |
| Enrollment | 62 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Feb 2, 2007 |
| Last update posted | Jan 27, 2014 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: